Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $51.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective boosted by HC Wainwright from $49.00 to $51.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also recently weighed in on SNDX. Stifel Nicolaus upped their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a report on Monday, October 14th. Citigroup upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Bank of America lifted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Barclays upped their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. dropped their target price on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.18.

Syndax Pharmaceuticals Trading Up 1.8 %

SNDX stock opened at $16.11 on Monday. Syndax Pharmaceuticals has a 1-year low of $14.97 and a 1-year high of $25.34. The firm has a market cap of $1.38 billion, a PE ratio of -4.44 and a beta of 0.92. The business’s 50-day moving average price is $18.87 and its two-hundred day moving average price is $20.19.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter last year, the firm earned ($0.73) EPS. On average, analysts forecast that Syndax Pharmaceuticals will post -3.61 earnings per share for the current year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock valued at $38,066,000 after acquiring an additional 66,459 shares during the last quarter. Barclays PLC raised its holdings in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after purchasing an additional 110,535 shares during the period. Y Intercept Hong Kong Ltd lifted its stake in Syndax Pharmaceuticals by 319.4% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock valued at $1,565,000 after purchasing an additional 61,916 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Syndax Pharmaceuticals by 7.7% during the third quarter. Two Sigma Advisers LP now owns 669,352 shares of the company’s stock worth $12,885,000 after purchasing an additional 48,100 shares during the period. Finally, Sphera Funds Management LTD. increased its position in Syndax Pharmaceuticals by 25.9% during the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock worth $19,921,000 after buying an additional 212,799 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).